HMG-CoA Reductase Inhibitors for Hypercholesterolemia

J. A. Tobert, B. R. Leslie, E. J. Schaefer, H. R. Van Buuren, M. G A Baggen, J. H P Wilson, Scott M Grundy

Research output: Contribution to journalLetter

45 Scopus citations

Abstract

To the Editor: In his review (July 7 issue)* of inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, Dr. Grundy concluded that these drugs are effective and usually well-tolerated cholesterol-lowering agents. He also pointed out, appropriately, that these compounds have not been given to large populations for long periods and, therefore, their adverse effects may not be fully defined. We would like to provide the interim results, as of May 1988, of a long-term study of lovastatin that began in 1984. In the study, long-term therapy with a lipid-lowering diet plus lovastatin is being evaluated in 744 patients in 23 centers.

Original languageEnglish (US)
Pages (from-to)1222-1223
Number of pages2
JournalNew England Journal of Medicine
Volume319
Issue number18
DOIs
StatePublished - Nov 3 1988

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'HMG-CoA Reductase Inhibitors for Hypercholesterolemia'. Together they form a unique fingerprint.

  • Cite this

    Tobert, J. A., Leslie, B. R., Schaefer, E. J., Van Buuren, H. R., Baggen, M. G. A., Wilson, J. H. P., & Grundy, S. M. (1988). HMG-CoA Reductase Inhibitors for Hypercholesterolemia. New England Journal of Medicine, 319(18), 1222-1223. https://doi.org/10.1056/NEJM198811033191811